Literature DB >> 12165810

Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer.

Hiroki Kuniyasu1, Yoshitomo Chihara, Tadahiko Kubozoe, Tadateru Takahashi.   

Abstract

Heparanase is an enzyme that degrades extracellular glycoprotein to release heparan sulfate molecules. CD44 variant exon 3 (CD44v3), a receptor for heparan sulfate, generates intracellular signals for cell migration. Production of CD44v3 and expression of heparanase were detected by immunohistochemistry and in situ hybridization, respectively. In 145 cases of colon cancer, heparanase mRNA and CD44v3 protein were detected in 46% and 43%, respectively. Co-expression of heparanase and CD44v3 was found in cases of 12% of Dukes' B, 32% of Dukes' C, and 57% of Dukes' D cases. Survival analysis found a significantly poorer prognosis in patients showing concurrent expression of heparanase and CD44v3 than in patients not showing both (p<0.0001). Concurrent expression of heparanase and CD44v3 might be a mechanism of cancer invasion and metastasis in colon cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165810

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  Cotransfection of survivin and CD44v3 short hairpin RNAs affects proliferation, apoptosis, and invasiveness of colorectal cancer.

Authors:  Zhonghong Liu; Yonghang Guo; Juan Li; Jun Xu; Bingrong Liu
Journal:  Dig Dis Sci       Date:  2013-02-03       Impact factor: 3.199

2.  CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.

Authors:  Shujie Zhao; Chen Chen; Katherine Chang; Anand Karnad; Jaishree Jagirdar; Addanki P Kumar; James W Freeman
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

3.  Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas.

Authors:  Jun-Qiang Chen; Wen-Hua Zhan; Yu-Long He; Jun-Sheng Peng; Jian-Ping Wang; Shi-Rong Cai; Jin-Ping Ma
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

4.  DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.

Authors:  Joseph P Connor; Mildred Felder; Arvinder Kapur; Nonyem Onujiogu
Journal:  BMC Cancer       Date:  2012-05-14       Impact factor: 4.430

5.  Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides.

Authors:  Xin-Zhong Chang; Zhan-Min Wang; Jin-Ming Yu; Fu-Guo Tian; Wei Jin; Yi Zhang; Jie Yu; Lian-Fang Li; Xiao-Feng Liu; Zhi-Wei Li; Zhi-Min Shao
Journal:  Clin Exp Metastasis       Date:  2007-01-27       Impact factor: 4.510

6.  Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significances.

Authors:  Juchao Ren; Hainan Liu; Lei Yan; Sujian Tian; Dawei Li; Zhonghua Xu
Journal:  World J Surg Oncol       Date:  2011-12-02       Impact factor: 2.754

Review 7.  Novel CD44-downstream signaling pathways mediating breast tumor invasion.

Authors:  Allal Ouhtit; Balsam Rizeq; Haissam Abou Saleh; Md Mizanur Rahman; Hatem Zayed
Journal:  Int J Biol Sci       Date:  2018-10-05       Impact factor: 6.580

8.  Upregulation of Fecal Epithelial Heparanase mRNA Is Associated with Increased Ulcerative Colitis Activity and Cancerization Risk.

Authors:  Ying Cui; Jun Zhang; Yan Chen; Le-Gao Chen
Journal:  Dig Dis Sci       Date:  2020-05-22       Impact factor: 3.199

9.  Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.

Authors:  Chen Chen; Shujie Zhao; Xiangru Zhao; Lin Cao; Anand Karnad; Addanki P Kumar; James W Freeman
Journal:  Cell Death Dis       Date:  2022-08-05       Impact factor: 9.685

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.